Table 3.
Risk factors associated with significant changes in percent predicted FEV1 from baseline to 4 months in subjects who were assigned to ipratropium bromide.
| Risk estimate | 95% CI | p-Value | |
|---|---|---|---|
| Sex (male versus females) | − 5.50 | (− 9.31, − 1.68) | < 0.01 |
| Age (per 1 year increase) | − 0.07 | (− 0.12, − 0.03) | < 0.01 |
| BMI (per 1 kg/m2 increase) | − 0.14 | (− 0.25, − 0.03) | < 0.05 |
| CO (per 1 ppm increase) | 0.02 | (0.01, 0.04) | < 0.01 |
| Smoking (per 1 pack-year increase) | 0.04 | (0.01, 0.07) | < 0.01 |
| Sex × BMI | 0.15 | (0.00, 0.30) | < 0.05 |
| Sex × pack-years | − 0.02 | (− 0.05, 0.01) | 0.233 |
Abbreviations: BMI, body mass index; CI, confidence interval; CO, carbon monoxide.